人才队伍

姓名:	梁兴杰	性别:	男
职务:	中国科学院纳米生物效应与安全性重点实验室副主任	职称:	研究员
通讯地址:	北京市海淀区中关村北一条11号
邮政编码:	100190	电子邮件:	liangxj(AT)nanoctr.cn

简历：

梁兴杰，国家杰出青年基金获得者(生物材料和纳米医学)，博士生导师。在中国科学院生物物理研究所，生物大分子国家重点实验室膜分子生物学室获得博士学位，其后在美国国立卫生研究院 (NIH) 国家肿瘤研究所 (NCI) 细胞生物学实验室 (LCB), 在NIH副院长美国科学院院士Michael M. Gottesman 博士研究组从事5年博士后研究，研究恶性肿瘤细胞对化疗药物cisplatin的分子和细胞耐药机理。之后在美国国家神经疾病与中风研究所 (NINDS), 帕特神经科学研究中心(Porter Neuroscience Research Center)，外科和分子肿瘤神经实验室工作，研究恶性脑灰质瘤的药物和基因治疗机理。回国前作为助理教授在Howard University医学院放射医疗系从事纳米药物分子在动物体内的分子和细胞成像研究。

梁兴杰研究员现为中国科学院纳米生物效应与安全性重点实验室副主任，中国科学院纳米科学卓越中心纳米药物组组长，中国生物物理学会理事，纳米生物学分会主任，中国药学会高级会员，《Current Drug Delivery》主编，《Biophysics Reports》和《Biomaterials》杂志副主编，《ACS Nano》建议编委会杂志编委,《Theranostics》, 《Biomaterials Research》，《Bioconjugate Chemistry》等杂志编委及《Biotechnology Advances》杂志客座编委。

研究方向为纳米药物的设计合成、结构优化和功能测定及其临床应用中的生物机制。

课题组欢迎具有细胞或分子生物学、药学、肿瘤学、免疫学、高分子、材料、化学、病理学或临床医学等相关专业的本科、硕士、博士学位或有博士后经历者到实验室进行短期或长期科研工作。

梁兴杰课题组主页

研究领域：
	纳米医学和纳米药学

社会任职：

获奖及荣誉：

2004，2005 和 2006 年连续三年获得美国国立卫生研究院“优秀科研奖”, 2010获得国务院政府有突出贡献专家(自然科学类)，2012年获得国家杰出青年基金，2012年获得中国药学会青年药物学家奖， 2014年获得国家质量监督检验检疫总局“科技兴检奖”。 2015 年中国科学院-BHHB（必和必拓）导师科研奖; 2016, 2018 年度中科院-沙特基础工业公司（SABIC-CAS）导师科研奖; 2017 中青年科技创新领军人才; 2018 年天津市自然科学奖一等奖。

代表论著：

Representative research articles as corresponding author *

1. Gong N. et al. Liang X.-J.* Carbon dot-supported atomically-dispersed gold (CAT-g) as a mitochondrial oxidative stress amplifier for cancer treatment. Nature Nanotechnology.2018.DOI:10.1038/s41565-019-0373-6 (in press)

2. Zhang T, et al. Liang XJ* Fluorinated Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-Containing Media by Effective Endosomal Escape. Nano Letter. 2018. 18(10):6301-6311.

3. Zhao Y, et al. Liang XJ*. Spatiotemporally Controllable Peptide-based Nanoassembly in Single Living Cells for a Biological Self-portrait. Advanced Materials 2017. 29,1601128.

4. Xue, X.; et al. Liang, X. J*. Aggregated single-walled carbon nanotubes attenuate the behavioural and neurochemical effects of methamphetamine in mice. Nature Nanotechnology 2016, 11 (7), 613-620.

5. Wei, T.; et al. Liang, X.J*. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. PNAS. (Proc Natl Acad Sci U S A.). 2015. 112 (10): 2978-2983.

6. Xue, X.; et al. Liang, X. J*. Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Letters 2014, 14 (9), 5110-5117.

7. Xue, X.; et al. Liang, X. J*. Spatiotemporal drug release visualized through a drug delivery system with tunable aggregation-induced emission. Advanced Materials 2014, 26 (5), 712-7.

8. Wei, T.; et al. Liang, X. J.* Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Letters 2013, 13 (6), 2528-34.

9. Huo, SD.; et al. Liang, X. J.* Superior penetration and retention behavior of 50nm gold nanoparticles in tumor. Cancer Research. 2013 73:319-330.

10. Liang, X.J. * et al. Metallofullerene Nanoparticles Circumvent Tumor Resistance to Cisplatin by Reactivating Endocytosis. PNAS. (Proc Natl Acad Sci U S A.). 2010. 107(16):7449-7454.

Representative review articles as corresponding author *:

1. Yufei Wang, Yuxuan Zhang, Jinjin Wang, Xing-Jie Liang*. AIE fluorophores as imaging tools to explore biological fate of nano-drug delivery systems. Advanced Drug Delivery Review. DOI：10.1016/j.addr.2018.12.004. (In press)

2. Ningqiang Gong; Yuxuan Zhang; Zhen Zhang; Xianlei Li; Xing-Jie Liang*. Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Advanced Functional Materials. 2018. 1806087 (1-16)

3. Xiao-Li Liu, Shizhu Chen, Huan Zhang, Jin Zhou, Hai-Ming Fan* and Xing-Jie Liang* Magnetic Nanomaterials for Advanced Regenerative Medicine: The Promise and Challenges. Advanced Materials. 2018. 12(4): e 1804922.

4. Yuxuan Zhang, Yufei Wang, Jinjin Wang and Xing-Jie Liang*. Pharmaceutical Research and Development Improved with AIE-based Nanostructures. Materials Horizons, 2018, 5, 799 – 812.

5. Yufei Wang, Juan Liu, Xiaowei Ma and Xing-Jie Liang* Nanomaterial-assisted sensitization of oncotherapy. Nano Research 2018. 11(6): 2932–2950.

6. Lu Liu, Weisheng Guo, Xing-Jie Liang*. Move to Nano-Arthrology: Targeted Stimuli-Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis. Biotechnology Journal. 2018. 1800024 (1-14).

7. Yifeng Wang , Lu Liu , Xue Xue , Xing-Jie Liang*. Nanoparticle-based drug delivery systems: What can they really do in vivo? F1000 Research. 2017. 6 (F1000 Faculty Rev):681 (doi: 10.12688/f1000research.9690.1)

8. Xiaowei Ma, Ningqiang Gong, Lin Zhong, Xing-Jie Liang *. Future of Nanotherapeutics: Targeting the Cellular Sub-organelles. Biomaterials. 2016. 97: 10-21.

9. Juan Liu, Yuran Huang, Anil Kumar, Aaron Tan, Shubin Jin, Anbu Mozhi, Xing-Jie Liang*. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances 2014.32(4): 693-710.

10. Xiao-wei Ma, Yuliang, Zhao, Xing-Jie Liang*. Theranostic Nanoparticles engineered for Clinic and Pharmaceutics. Accounts of Chemical Research. 2011. 44(10): 1114–1122

Representative articles before working at nanocenter：

1. Liang, X. J.*, Shen, D.W., Yin, J.J., Aszalos, A., and Gottesman, M. M. SIRT1 contributes to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Molecular Cancer Research. 2008, 6(9):1499-1506.

2. Liang, X.J., Choi, Y., Sackett, D.L. and Park, J.K. Inhibition of stathmin enhances CCNU blocking glioma cell migration and invasion. Cancer Research. 2008, 68(13):5267-5272.

3. Hall MD, Okabe M, Shen, DW, Liang, XJ, and Gottesman, MM. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology. 2008，48: 495-535.

4. Ngo.T.B*, Peng T., *, Liang X.J *., Akeju O., Pastorino S., Zhang W., Fine H.A., Maric D., Wen P.Y., Girolami U.D., Black P.M., Wu W., Shen R.F., Kang D.W., and Park J.K. The 1p encoded protein stathmin modulates the response of malignant gliomas to nitrosoureas. Journal of National Cancer Institute. 2007, 99: 639-652.

5. Liang, X. J., Mukherjee, S., Shen, D. W., Maxfield, F. R. and Gottesman, M. M. Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells . Cancer Research. 2006, 66 (4): Feb 15; 2346-2353.

6. Liang, X. J., Shen, D. W., Chen G. K., Wincovitch S. M., Garfield, S., and Gottesman, M. M. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. Journal of Cellular Physiology. 2005, 202 (3): 635-641.

7. Liang, X.J, Shen, D.W, and Gottesman, M.M. Down-regulation and altered localization of g-catenin in cisplatin-resistant adenocarcinoma cells. Molecular Pharmacology. 2004 65 (5): 1217-1224.

8. Liang, X.J, Shen, D.W, and Gottesman, M.M. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry. 2004 (98) 1599-1606.

9. Liang, X.J, Yin, J.J., Zhou, J.W., Wang, P. C., Taylor, B., Cardarelli, C., Kozar, M, Forte, R., Aszalos, A.and Gottesman, M. M. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental Cell Research. 2004, 293: 283-291.

10. Liang, X. J., Shen, D. W., Garfield, S., and Gottesman, M. M. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistanct cancer cell lines. Cancer Research. 2003, 63: 5909-5916.

Book Chapters:

1. Gottesman, M.M., Hall, M.D., Liang, X.J., and Shen, D.W.: Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. In Bonetti, A. Leone, R. Muggia, F. Howell, S.B. (Eds.): Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. Humana Press, Totowa, New Jersey, 2009, 83-88.

2. Liang, X.J., Chen, C.Y., Zhao, Y.L., Wang, P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer Series: Methods in Molecular Biology , Zhou, Jun (Ed.), Humana Publisher, New York, 2010; 596: 467-488.

3. Tan, J., Liu, C., Hu, L., Wang, C and Liang, X.J. The State of the Science: a 5-Year Review on the Computer-Aided Design for Global Anti-AIDS Drug Development. HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, Eugenia Barros (Edited), 2011, INTECH open access publisher, ISBN978-953-307-343-9. 2011, 25-46.

4. Liang, X.J. Editing “Nanopharmaceuticals: Potential Application of Nanomaterials. (approx. 800pp) World Scientific Publication Press, New Jersey, 2012. ISBN: 978-981-436-866-7.

5. Xue, X., Liang, X.J. Multifunctional Nanoparticles for Theranostics and Imaging. Nanomedicine: Nanostructure Science and Technology. Springer New York. 2014, pp 101-115.

6. 梁兴杰、 杨科妮、李盛亮、王重夕、金叔宾等。第6章 纳米辅料的药学应用。阎锡蕴主编 科学出版社。2014. Page 281-336

7. Huo, S., Cao, X., Hu, Z. and Liang, X.J. Gold Nanoparticles: A Novel and Promising Avenue for Drug Delivery. Chapter 2 in Section I？Nanomaterials for Drug Delivery. Biological and Pharmaceutical Application of Nanomaterials. Polina Prokopovich (eds.). CRC Press, Taylor & Francis Group. Florida. 2015, pp 39-53.

8. Zhang T, Zhang C, Xing J, Xu J, Li C, Wang P andLiang XJ. Multifuctional Dendrimers for Drug Nanocarriers . Chapter 10. Handbook of Research on Novel Approaches for Drug Delivery (ISSN: 2327-9354; eISSN: 2327-9370). 2016. P245-276.

9. 《医用材料概论》人民卫生出版社 全国生物医学工程（临床工程）专业教材。胡盛寿院士 中国医学科学院阜外医院院长 主编。 副主编：奚廷斐 孔德领 王琳。第二章 医用材料分类 第七节 医用纳米材料 梁兴杰编著

10. Ruslan G. Tuguntaev, Ahmed Shaker Eltahan, Satyajeet S. Salvi, and Xing-Jie Liang*. Chapter 12. Drug Targeting: Principles and Applications. Apple Academic Press ？for？？the book Drug Delivery Approaches and Nanosystems, Vol I: Novel Drug Carriers. 2017. July 30, 2017 by Apple Academic Press. Reference - 425 Pages. ISBN 9781771885836 - CAT# N11892.

11. 全国科学技术名词审定委员会《生物物理学名词》，2018.。科学出版社。

承担科研项目情况：

1. 中芬纳米科学国际合作项目，2008-2010 2. 科技部纳米科学重大基础研究计划, 2009-2013 项目负责人 3. 国家自然科学基金委重点项目, 2014-2017 和 2017-2020 项目负责人 4. 科技部基因治疗研究计划，2012-2016 课题负责人 5. 国家自然基金委杰出青年资助项目， 2013-2016课题负责人 6. 中国科学院纳米药物先导专项, 2014-2018. 子项目负责人 7. 国家自然科学基金委重点项目, 2017-2021 和 NSFC-DFG grant 2018-2020 项目负责人.